Tekcapital plc Market Research Report: Belluscura plc (1153K)
20 Avril 2020 - 8:00AM
UK Regulatory
TIDMTEK
RNS Number : 1153K
Tekcapital plc
20 April 2020
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulations (EU) No. 596/2014 ("MAR"). With the
publication of this announcement via a Regulatory Information
Service ("RIS"), this inside information is now considered to be in
the public domain.
20 April 2020
Tekcapital plc
("Tekcapital" or the "Company")
Market Research Report: Belluscura plc
New Report Estimates the global medical oxygen concentrator
and
oxygen cylinder market will reach $3.7b by 2026
Tekcapital plc, (AIM: TEK) the UK intellectual property
investment group focused on creating marketplace value from
university technology, announces that a new report by Grand View
Research estimating global medical sales of portable oxygen
concentrators and cylinders has been published(1) .
Amongst other factors, the report examines the impact of new
data from the COVID-19 pandemic on market demand. The report
highlights an increasing demand for portable oxygen concentrators,
and anticipates unit sales to grow from 405k units per year in 2019
to 581k units per year in 2026 for a total value of $1.4bn. This
anticipated growth may have a positive impact on portfolio company
Belluscura. View the report here .
Additionally, a new study indicates recovered COVID-19 patients
can be left with damaged lungs. Further investigations of the
recovered COVID-19 patients must now be conducted to show whether
they have developed pulmonary fibrosis - scarring in the lungs(2)
.
Belluscura's first product, the X-PLO(2) R(TM) portable oxygen
concentrator is currently awaiting FDA clearance, which is
anticipated in H1 2020.
According to Tekcapital director Robert Miller, M.D., "A portion
of the patients who recover from COVID-19 may present residual lung
damage, necessitating the use of supplemental oxygen."
About Belluscura plc
Belluscura is focused on developing novel oxygen-based treatment
platforms that can be adapted and applied in a wide range of
markets beyond those traditionally applicable to a single product
or product line. Belluscura is developing innovative enriched
oxygen treatment platforms that reduce the cost of treatment and
increase available treatment options. To learn more about
Belluscura, please visit www.belluscura.com .
Tekcapital owns 18.9% of the share capital of Belluscura.
About Tekcapital plc
Tekcapital creates value from investing in new,
university-developed intellectual properties and provides a range
of IP investment services to make it easy for organisations to
commercialise university-developed technology. Tekcapital is quoted
on the AIM market of the London Stock Exchange (AIM: symbol TEK)
and is headquartered in Oxford, in the UK. For more information,
please visit www.tekcapital.com .
LEI: 213800GOJTOV19FIFZ85
For further information, please contact:
Tekcapital Plc Via Flagstaff
Clifford M. Gross, Ph.D.
SP Angel Corporate Finance LLP (Nominated
Adviser and Joint Broker) +44 (0) 20 3470 0470
Richard Morrison/Charlie Bouverat (Corporate
Finance)
Abigail Wayne (Corporate Broking)
Novum Securities Limited (Joint Broker) +44 (0) 20 7399 9427
Colin Rowbury (Corporate Broking)
Flagstaff Strategic and Investor Communications +44 (0) 20 7129 1474
Tim Thompson/Andrea Seymour/Fergus Mellon
References
1- https://drive.google.com/file/d/1s5Ou0UQWwjUfWAZ4TNcVMAtsBivvH9r5/view
2-
https://www.dw.com/en/covid-19-recovered-patients-have-partially-reduced-lung-function/a-52859671
Forward Looking Statements
This press release is for informational purposes only. The
information herein does not constitute investment advice nor an
offer to invest and may contain statements related to our future
business and financial performance and future events or
developments involving Tekcapital or Belluscura that may constitute
forward-looking statements. These statements may be identified by
words such as "expect," "look forward to," "anticipate" "intend,"
"plan," "believe," "seek," "estimate," "will," "project" or words
of similar meaning. We may also make forward-looking statements in
other reports, in presentations, in material delivered to
customers, stakeholders and in press releases. In addition, our
representatives may from time to time make oral forward-looking
statements. Such statements may be based on the current
expectations and certain assumptions of Tekcapital or Belluscura's
management. Please note that these are subject to a number of
risks, uncertainties and factors, including, but not limited to
those described in various disclosures. Should one or more of these
risks or uncertainties materialize, or should underlying
expectations not occur or assumptions prove incorrect, actual
results, performance or achievements of Belluscura may vary
materially from those described explicitly or implicitly in the
relevant forward-looking statement. Neither Tekcapital nor
Belluscura intends, nor assumes any obligation, to update or revise
these forward-looking statements in light of developments which
differ from those anticipated.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
RESFLFFTSIIALII
(END) Dow Jones Newswires
April 20, 2020 02:00 ET (06:00 GMT)
Tekcapital (LSE:TEK)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Tekcapital (LSE:TEK)
Graphique Historique de l'Action
De Août 2023 à Août 2024